NANO MRNA Co.,Ltd. (TYO:4571)

Market Cap	10.31B
Revenue (ttm)	108.00M
Net Income (ttm)	-835.00M
Shares Out	70.60M
EPS (ttm)	-11.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	494,100
Average Volume	970,375
Open	150.00
Previous Close	150.00
Day's Range	145.00 - 150.00
52-Week Range	113.00 - 230.00
Beta	n/a
RSI	60.65
Earnings Date	Aug 8, 2025

About NANO MRNA

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 18
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4571

Financial Performance

In 2024, NANO MRNA's revenue was 108.00 million, a decrease of -20.00% compared to the previous year's 135.00 million. Losses were -835.00 million, 7.05% more than in 2023.